A Phase 1 interventional study of Zileuton extended release in Food Allergies, sponsored by Abigail Lang. Recruiting at 1 site in United States. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-11-13.
Sponsored by Abigail Lang · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 139 studies in Food Hypersensitivity with a site in United States — 20 open to participants now, 28 under way, 3 of them phase 3. Food Hypersensitivity · United States.
Among the 139 studies in Food Hypersensitivity with a site in United States, this one is the 79th largest by planned enrollment of the 105 interventional ones that give a count, is one of 6 that started in 2026, is one of 18 in phase 1, reaches primary completion later than 15 of the 27 other live ones, and was the 139th registered.
378 studies on the registry are indexed under Food Hypersensitivity; 92 are open to participants now.
Browse Food Hypersensitivity studies →20 of the 139 studies in Food Hypersensitivity with a site in United States are open now. Recruiting first, the newest first:
Johns Hopkins University · Sites in United States
Ages 1–30
Novartis Pharmaceuticals · Sites in United States
Ages 12–65
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 12 mo–17 yrs
Stanford University · Sites in United States
Ages 4 mo–11 mo · Healthy volunteers
Massachusetts General Hospital · Sites in United States
Ages 1–55
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 54 Food Hypersensitivity studies recruiting now, 8 (15%) set no upper age limit and 42 (78%) stop at 75 or younger; 46 take children under 18; 17 take healthy volunteers.
This study: 12 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
139 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 33 · Phase 2 49 · Phase 3 7 · Phase 4 3
First in 1996; this study’s year is marked. 6 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 60 across 248 interventional studies indexed under Food Hypersensitivity.
Median enrollment 41 across the 105 interventional studies, 270 across the 33 observational. Of the 99 that completed or were terminated, 50 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 139 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Abigail Lang as lead sponsor.
Abigail Lang has 1 study filed under Food Hypersensitivity — fewer than ten, so there is no comparison to draw.
11 of the studies in Food Hypersensitivity with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07003919Phase 3DBV TechnologiesSafety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers) | 2026-11 |
| NCT06034678Children's National Research InstituteEvaluation of The Food Allergy Mastery Program | 2026-11-30 |
| NCT04222491Massachusetts General HospitalFood Oral Immunotherapy for Peanut Allergy | 2026-12 |
| NCT05584488Columbia UniversityAllergy and Immunology Natural History Study | 2027-01 |
| NCT05695261Rima RachidEvaluating the Safety and Efficacy of Oral Encapsulated Microbiota Transplantation Therapy in Peanut Allergic Patients | 2027-01-11 |
Add all 11 to your calendar (.ics) → With an account.
Among the 139 studies in Food Hypersensitivity with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Our proposed project will seek to determine if an oral medication called zileuton, which blocks the synthesis of inflammatory molecules called leukotrienes that are involved in allergic reactions, may be able to decrease absorption of food allergens and prevent severe food allergy reactions from occurring. Our study will measure levels of peanut in the blood before and after subjects consume an allergen they can tolerate and compare the results with and without administration of the study medication, zileuton. If our study shows that zileuton can decrease the absorption of a food allergen, this will allow us to see if this medication can be used to prevent anaphylaxis to food.
The goal of this proof-of-concept study is to determine whether zileuton inhibits food allergen absorption in children and adolescents with food allergy. The main questions it aims to answer are:
Researchers will compare levels of peanut allergen proteins in the participants' blood with and without a dose of zileuton prior to a test meal of peanut protein.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Known IgE-mediated food allergy other than peanut
Confirmed by clinical history of reaction to the food antigen plus
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Treatment with a single dose of Zileuton administered at Visit 2.
Drug: Zileuton extended release
Zileuton is available in 600 mg strength yellow-colored oval tablets. A single dose of 1200 mg zileuton ER (two 600 mg zileuton tablets) will be administered to each participant.
Also known as: Zyflo
Inhibition of food allergy absorption by zileuton
Comparison of serum peanut antigen levels pre- and post-peanut test meal will be performed in each participant for Visit 1 (baseline) and Visit 2 (with study drug) to determine absorption of peanut. Comparison of post-meal peanut levels with and without zileuton treatment in each participant will also be performed to see whether gut permeability to peanut changes with study drug administration.
Time frame: 1.25 hours pre-meal and 1 hour post-test meal (Visit 1, Baseline); 2.25 hours pre-test meal and 0.25, 0.5, 1 hour post-test meal (Visit 2, 7 days after Visit 1)
Variability in allergen absorption in children and adolescents with food allergy
Comparison of peanut antigen levels between participants to assess any variability in absorption of food antigens between individuals.
Time frame: 1.25 hours pre-meal and 1 hour post-test meal (Visit 1, Baseline); 2.25 hours pre-test meal and 0.25, 0.5, 1 hour post-test meal (Visit 2, 7 days after Visit 1)
Plan to share: Undecided
Start is estimated for Nov 2026; primary completion for Dec 2027, 13 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Zileuton